1. Fig. 2. Changes in blood pressure, body weight, and echocardiographic findings. (A) Mean blood pressure was significantly decreased in the fimasartan-treated group (High-fima and Low-fima) compared with the normal control group at week eight from baseline. (B) Body weight increased in all animals until week three from baseline, and then decreased in all animals administered with DOX. At eight weeks, the DOX-only group showed the lowest body weight. (C) LVEF also decreased in the DOX-only group at eight weeks. In contrast, body weight and LVEF were preserved in High-fima and Low-fima groups. (D) LV end-systolic dimension (ESD) progressively increased in the DOX-only group; however, LV dilatation was attenuated in Low-fima and High-fima groups (*P < 0.05 compared to NC group, †P < 0.05 compared to DOX-only group).
Fig. 2. Changes in blood pressure, body weight, and echocardiographic findings. (A) Mean blood pressure was significantly decreased in the fimasartan-treated group (High-fima and Low-fima) compared with the normal control group at week eight from baseline. (B) Body weight increased in all animals until week three from baseline, and then decreased in all animals . . .
J Korean Med Sci May;30(5):